| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Bouafia, Abderrhmane
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (4/4 displayed)
- 2024Eco-Friendly Synthesis of Al2O3 Nanoparticles: Comprehensive Characterization Properties, Mechanics, and Photocatalytic Dye Adsorption Studycitations
- 2024Nanostructured Mn@NiO composite for addressing multi-pollutant challenges in petroleum-contaminated watercitations
- 2024Green synthesis of Mn 3 O 4 @CoO nanocomposites using Rosmarinus officinalis L. extract for enhanced photocatalytic hydrogen production and CO 2 conversioncitations
- 2023High-efficiency photocatalytic degradation of antibiotics and molecular docking study to treat the omicron variant of COVID-19 infection using biosynthesized ZnO@Fe<sub>3</sub>O<sub>4</sub> nanocompositescitations
Places of action
| Organizations | Location | People |
|---|
article
High-efficiency photocatalytic degradation of antibiotics and molecular docking study to treat the omicron variant of COVID-19 infection using biosynthesized ZnO@Fe<sub>3</sub>O<sub>4</sub> nanocomposites
Abstract
<jats:title>Abstract</jats:title><jats:p>In this study, ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> nanocomposite (NC) was synthesized using a green synthesis method with <jats:italic>Mentha pulegium</jats:italic> leaf extract. Characterization techniques such as UV–vis, FTIR, SEM, TGA, and XRD were employed to confirm the formation of ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> NC and thermogravimetric analysis to evaluate the breakdown of NC in the presence of heat. XRD analysis showed a crystallite size of about 25.59 nm and SEM images of ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> NC revealed spherical-shaped agglomerated particles. The optical bandgap energy of the ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> NC was estimated to be 2.51 eV for direct bandgap and 1.57 eV for allowable indirect bandgap. Photocatalytic activity of the ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> NC was evaluated for the degradation of Amoxicillin, Cephalexin, and Metronidazole antibiotics under sunlight irradiation, showing degradation efficiencies of 71%, 69%, and 99%, respectively, suggesting the potential of ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> NC for removal of antibiotics from waterways. First-principles theory was employed to establish the adsorption energy (E<jats:sub>ad</jats:sub>) of the antibiotic species, including Amoxicillin, Cephalexin, and Metronidazole, on the surface of ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> nanocomposite, which was found to be −8.064, −8.791, and −21.385 eV, respectively, indicating strong adsorption. Furthermore, molecular docking studies were conducted to upgrade Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> nanoparticles to ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> NC to enhance composite efficiency. Leveraging the FDA-approved use of Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> nanoparticles and their known antiviral activity, our docking experiment demonstrated promising results in the interaction between ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> nanocomposite and the spike protein receptor-binding domain of SARS-CoV-2 S Omicron. These findings suggest that ZnO@Fe<jats:sub>3</jats:sub>O<jats:sub>4</jats:sub> nanocomposite could potentially inhibit virus attachment to host cell receptors more stably, providing a promising avenue for further exploration in developing effective medications against SARS-CoV-2.</jats:p>